Terumo, Marker Therapeutics get authorisation for blood purification device

Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics AG’s D2000 Adsorption Cartridge has the potential to reduce the levels of inflammatory cytokines responsible for acute respiratory failure in Covid-19 patients. Credit: Terumo BCT, PR000.